AVI BIOPHARMA - Schweinegrippe-Profiteur
Seite 3 von 6 Neuester Beitrag: 29.11.12 14:30 | ||||
| Eröffnet am: | 27.04.09 19:22 | von: Fortunatus | Anzahl Beiträge: | 133 |
| Neuester Beitrag: | 29.11.12 14:30 | von: MeinMotto | Leser gesamt: | 38.871 |
| Forum: | Hot-Stocks | Leser heute: | 1 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | | 4 | 5 | 6 > | ||||
Einzig Sinovac, ein Unternehmen, dass mit der chin. Regierung zusammenarbeitet, performt noch sehr stark. Ich glaub da hatte der Aktionär auch mal was drüber geschrieben.
Ich warte jetzt erstmal auf etwas günstigere Kurse.
http://www.marketwire.com/press-release/...c-NASDAQ-AVII-1006881.html
AVI BioPharma Under Contract With U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu
PORTLAND, OR--(Marketwire - June 22, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency (DTRA) for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.
The material terms of this contract were previously announced by AVI on May 5, 2009 in a regulatory filing (8-K) with the U.S. Securities and Exchange Commission regarding a funding award of up to $5.1 million. The objective of the contract is to accomplish the preclinical development of one or more medical countermeasures based on AVI's proprietary antisense Phosphorodiamidate Morpholino Oligonucleotide (PMO) backbone and demonstrate efficacy using an appropriate animal model.
Under the contract, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The Company will also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.
Additional information regarding the DTRA contract can be found at: https://www.fbo.gov/download/cbb/...ef9/HDTRA1-09-C-0046_J&A_.pdf
About Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. http://www.dtra.mil/index.cfm.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI BioPharma Under Contract with U.S. Defense Threat Reduction Agency for Development of Therapeutics Targeting H1N1 Swine Flu...
PORTLAND, OR -- (MARKET WIRE) -- 06/22/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, is under contract with the U.S. Defense Threat Reduction Agency (DTRA) for development of one or more nucleotide-based candidate drugs targeting the present epidemic of H1N1 swine flu.
The material terms of this contract were previously announced by AVI on May 5, 2009 in a regulatory filing (8-K) with the U.S. Securities and Exchange Commission regarding a funding award of up to $5.1 million. The objective of the contract is to accomplish the preclinical development of one or more medical countermeasures based on AVI's proprietary antisense Phosphorodiamidate Morpholino Oligonucleotide (PMO) backbone and demonstrate efficacy using an appropriate animal model.
Under the contract, AVI will analyze the H1N1 sequence, determine appropriate targets and identify lead and back-up candidate drugs. The Company will also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.
Additional information regarding the DTRA contract can be found at: https://www.fbo.gov/download/cbb/...ef9/HDTRA1-09-C-0046_J&A_.pdf
About Defense Threat Reduction Agency
The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense that address the weapons of mass destruction (WMD) threat. The mission of the DTRA is to safeguard America and its allies from WMD (e.g. chemical, biological, radiological, nuclear, and high yield explosives) by providing capabilities to reduce, eliminate, and counter the threat, and mitigate its effects. Under DTRA, Department of Defense resources, expertise and capabilities are combined to ensure the United States remains ready and able to address the present and future WMD threats. http://www.dtra.mil/index.cfm.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI Press and Investor Contact:
Julie Rathbuninvestorrelations@avibio.com
(541) 224-2575
AVI BioPharma signs agreement with US Defense Threat Reduction Agency for H1N1 Swine Flu therapeutics Deal In Brief
Monday June 22, 2009 14:46:35 EDT
Jun 22, 2009 (Datamonitor Financial Deals Tracker via COMTEX News Network) --
AVI BioPharma, Inc., a developer of RNA-based drugs, has signed an agreement with the US Defense Threat Reduction Agency (DTRA) for the development of one or more nucleotide-based candidate drugs targeting the epidemic of H1N1 swine flu. DTRA is a division of US Department of Defense. Both the partners are based in the US.
Under the terms of the agreement, AVI BioPharma would analyze the H1N1 sequence, determine appropriate targets, and identify lead and back-up candidate drugs. AVI BioPharma would also manufacture development grade material in sufficient quantities for planned animal tests and perform animal studies for lead and back-up candidate drugs.
As part of the agreement, DTRA would pay up to $5.1 million to AVI BioPharma for the work. The work would involve the application of the AVI BioPharma's propriety PMOplus antisense chemistry.
Deal Type Partnership Sub-Category Research and discovery,Development Deal Status Announced: 2009-06-2209:35 23.06.09
Endingen (aktiencheck.de AG) - Die Experten von "Global Biotech Investing" raten bei der Aktie von AVI BioPharma (Profil) mit einer kleinen spekulativen Position aufzuspringen.
Das New Yorker AnaIystenhaus Maxim Group traue dem Papier ein Ziel von USD 3,50 zu! Das sei selbst nach der fantastischen Rally der letzten Wochen, in der sich der Anteilsschein bereits mehr als verdreifacht habe, ein weiteres Upside von satten 150%. AVI BioPharma sei ein Impfstoffforscher, der sich mittels seines auf der RNA- Technologieplattform basierenden Präparates Neugene einen Namen im Kampf gegen das Ebola-Virus gemacht habe. Tests hätten ergeben, dass der Wirkstoff effektiv gegen verschiedene Grippestämme eingesetzt werden könne. Die Hoffnungen lägen nun darin, dass das Unternehmen diesen Effekt auch auf das Schweinegrippe-Virus H1N1 übertragen könne. In Expertenkreisen würden der RNA-Technologie des Unternehmens bei einer möglichen Mutation des H1N1-Erregers die besten Chancen zugeschrieben.
In Regierungskreisen werde dies offensichtlich ähnlich gesehen und so habe AVI BioPharma bei seinen Forschungstätigkeiten zuletzt Unterstützung von höchster Ebene erhalten: Das US-Verteidigungsministerium habe dem Unternehmen drei Aufträge zur Entwicklung von Präparaten gegen mögliche terroristische Angriffe mit Biowaffen erteilt. Das Gesamtvolumen solle dabei rund USD 7 Mio. betragen.
Die Experten von "Global Biotech Investing" empfehlen bei der Aktie von AVI BioPharma mit einer kleinen spekulativen Position aufzuspringen und das gute Momentum mitzureiten. Das Investment sollte unbedingt mittels Stopp abgesichert werden. (Ausgabe 12 vom 22.06.2009) (23.06.2009/ac/a/a)
http://www.ariva.de/..._aufspringen_Global_Biotech_Investing_n3004716
AVI BioPharma Joining Russell 3000 Index
PORTLAND, OR -- (MARKET WIRE) -- 06/26/09 -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that immediately following the close of the U.S. markets today it will join the broad-market Russell 3000® Index following Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes.
The annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes. The Russell 3000 also serves as the U.S. component to the Russell Global Index, which Russell launched in 2007.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
AVI Press and Investor Contact:
Julie Rathbuninvestorrelations@avibio.com
(541) 224-2575
Absolut keine Aussagekraft egal ob im Minus oder Plus Bereich.